Marc Abrams

2.8k total citations
41 papers, 1.6k citations indexed

About

Marc Abrams is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Marc Abrams has authored 41 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 14 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Marc Abrams's work include RNA Interference and Gene Delivery (15 papers), MicroRNA in disease regulation (10 papers) and Advanced biosensing and bioanalysis techniques (8 papers). Marc Abrams is often cited by papers focused on RNA Interference and Gene Delivery (15 papers), MicroRNA in disease regulation (10 papers) and Advanced biosensing and bioanalysis techniques (8 papers). Marc Abrams collaborates with scholars based in United States, France and Japan. Marc Abrams's co-authors include Laura Sepp‐Lorenzino, Bin Shi, Noreen M. Robertson, Eric Wickstrom, Weimin Wang, Kyonggeun Yoon, Satdarshan P. Monga, Martin L. Koser, Shanthi Ganesh and Alan B. Sachs and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Journal of Clinical Oncology.

In The Last Decade

Marc Abrams

40 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marc Abrams United States 22 1.1k 281 236 163 161 41 1.6k
Hsiang Fu Kung Hong Kong 28 900 0.8× 511 1.8× 216 0.9× 304 1.9× 92 0.6× 39 1.7k
Ryouichi Tsunedomi Japan 22 671 0.6× 610 2.2× 335 1.4× 207 1.3× 124 0.8× 64 1.3k
Xing Gu China 17 621 0.5× 174 0.6× 203 0.9× 187 1.1× 105 0.7× 60 1.0k
Bisheng Zhou China 21 924 0.8× 302 1.1× 399 1.7× 148 0.9× 65 0.4× 41 1.4k
Yuhua Xue China 19 1.1k 1.0× 206 0.7× 109 0.5× 215 1.3× 107 0.7× 67 1.7k
Takuya Fukazawa Japan 26 1.1k 1.0× 545 1.9× 364 1.5× 157 1.0× 94 0.6× 75 1.8k
Jeff X. Zhou China 18 581 0.5× 312 1.1× 165 0.7× 214 1.3× 86 0.5× 35 1.3k
Gerald Timelthaler Austria 17 488 0.4× 272 1.0× 137 0.6× 186 1.1× 94 0.6× 40 942
Midori Hayashida Japan 11 773 0.7× 388 1.4× 136 0.6× 244 1.5× 77 0.5× 15 1.1k

Countries citing papers authored by Marc Abrams

Since Specialization
Citations

This map shows the geographic impact of Marc Abrams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Abrams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Abrams more than expected).

Fields of papers citing papers by Marc Abrams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Abrams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Abrams. The network helps show where Marc Abrams may publish in the future.

Co-authorship network of co-authors of Marc Abrams

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Abrams. A scholar is included among the top collaborators of Marc Abrams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Abrams. Marc Abrams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lai, Cheng-Jung, Jessica J. Gierut, Utsav Saxena, et al.. (2018). Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria. Molecular Therapy. 26(8). 1983–1995. 83 indexed citations
3.
Ganesh, Shanthi, et al.. (2018). RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade. Molecular Therapy. 26(11). 2567–2579. 88 indexed citations
4.
Gierut, Jessica J., Wei Zhou, Michael Dills, et al.. (2018). Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases. Molecular Therapy. 26(7). 1771–1782. 22 indexed citations
5.
Ganesh, Shanthi, et al.. (2018). Abstract B03: RNAi-mediated β-catenin inhibition sensitizes noninflamed tumors to immune checkpoint blockade. Cancer Immunology Research. 6(9_Supplement). B03–B03. 1 indexed citations
6.
Ganesh, Shanthi, Martin L. Koser, Cheng-Jung Lai, et al.. (2017). β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models. Molecular Cancer Therapeutics. 17(2). 544–553. 18 indexed citations
7.
Ganesh, Shanthi, Martin L. Koser, Junyan Tao, et al.. (2016). Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin. Molecular Cancer Therapeutics. 15(9). 2143–2154. 50 indexed citations
8.
Barrett, Stephanie E., Marc Abrams, Rob S. Burke, et al.. (2014). An in vivo evaluation of amphiphilic, biodegradable peptide copolymers as siRNA delivery agents. International Journal of Pharmaceutics. 466(1-2). 58–67. 13 indexed citations
9.
Seitzer, Jessica, et al.. (2010). Effect of biological matrix and sample preparation on qPCR quantitation of siRNA drugs in animal tissues. Journal of Pharmacological and Toxicological Methods. 63(2). 168–173. 14 indexed citations
10.
Abrams, Marc, Martin L. Koser, Jessica Seitzer, et al.. (2009). Evaluation of Efficacy, Biodistribution, and Inflammation for a Potent siRNA Nanoparticle: Effect of Dexamethasone Co-treatment. Molecular Therapy. 18(1). 171–180. 165 indexed citations
11.
Stratford, Suzanne, et al.. (2008). Examination of real-time polymerase chain reaction methods for the detection and quantification of modified siRNA. Analytical Biochemistry. 379(1). 96–104. 30 indexed citations
12.
13.
Quadros, Marlene R.D., Sharon Connelly, Csaba Kari, et al.. (2006). EGFR-dependent downregulation of bim in epithelial cells requires MAPK and PKC-δ activities. Cancer Biology & Therapy. 5(5). 498–504. 23 indexed citations
14.
Cesarone, Gregory, Cecilia Garofalo, Marc Abrams, et al.. (2006). RNAi‐mediated silencing of insulin receptor substrate 1 (IRS‐1) enhances tamoxifen‐induced cell death in MCF‐7 breast cancer cells. Journal of Cellular Biochemistry. 98(2). 440–450. 37 indexed citations
15.
Abrams, Marc, Noreen M. Robertson, Gerald Litwack, & Eric Wickstrom. (2005). Evaluation of glucocorticoid sensitivity in 697 pre-B acute lymphoblastic leukemia cells after overexpression or silencing of MAP kinase phosphatase-1. Journal of Cancer Research and Clinical Oncology. 131(6). 347–354. 8 indexed citations
16.
Dinsmore, Christopher J., C. Blair Zartman, Jeffrey M. Bergman, et al.. (2004). Macrocyclic piperazinones as potent dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I. Bioorganic & Medicinal Chemistry Letters. 14(3). 639–643. 8 indexed citations
17.
Tucker, Thomas J., Marc Abrams, Carolyn A. Buser, et al.. (2002). The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases. Bioorganic & Medicinal Chemistry Letters. 12(15). 2027–2030. 13 indexed citations
18.
Huber, Hans E., R. Robinson, Deborah D. Nahas, et al.. (2001). Anions Modulate the Potency of Geranylgeranyl-Protein Transferase I Inhibitors. Journal of Biological Chemistry. 276(27). 24457–24465. 16 indexed citations
19.
Bergman, Jeffrey M., Marc Abrams, Joseph P. Davide, et al.. (2001). Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I. Bioorganic & Medicinal Chemistry Letters. 11(11). 1411–1415. 25 indexed citations
20.
Dou, Yali, Craig A. Mizzen, Marc Abrams, C. David Allis, & Martin A. Gorovsky. (1999). Phosphorylation of Linker Histone H1 Regulates Gene Expression In Vivo by Mimicking H1 Removal. Molecular Cell. 4(4). 641–647. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hsiang Fu Kung Breakdown of academic impact, for papers by Ryouichi Tsunedomi Breakdown of academic impact, for papers by Xing Gu Breakdown of academic impact, for papers by Bisheng Zhou Breakdown of academic impact, for papers by Yuhua Xue Breakdown of academic impact, for papers by Takuya Fukazawa Breakdown of academic impact, for papers by Jeff X. Zhou Breakdown of academic impact, for papers by Gerald Timelthaler Breakdown of academic impact, for papers by Midori Hayashida
Rankless by CCL
2026